PDF(Pubmed)
Abstract：
Esophagogastric junction cancer (EGJC) is a rare malignant disease that occurs in the gastroesophageal transition zone. In recent years, its incidence has been rapidly increasing not only in Western countries but also in East Asia, and it has been attracting the attention of both clinicians and researchers. EGJC has a worse prognosis than gastric cancer (GC) and is characterized by complex lymphatic drainage pathways in the mediastinal and abdominal regions. EGJC was previously treated in the same way as GC or esophageal cancer, but, in recent years, it has been treated as an independent malignant disease, and treatment focusing only on EGJC has been developed. A recent multicenter prospective study revealed the frequency of lymph node metastasis by station and established the optimal extent of lymph node dissection. In perioperative treatment, the combination of multi-drug chemotherapy, radiation therapy, molecular targeted therapy, and immunotherapy is expected to improve the prognosis. In this review, we summarize previous clinical trials and their important evidence on surgical and perioperative treatments for EGJC.
摘要：
食管胃结合部癌(EGJC)是一种罕见的发生于胃食管过渡区的恶性疾病。近年来,它的发病率不仅在西方国家而且在东亚都迅速增加，它引起了临床医生和研究人员的注意。EGJC的预后比胃癌（GC）差，其特征是纵隔和腹部区域的淋巴引流途径复杂。EGJC以前以与GC或食道癌相同的方式治疗，但是,近年来,它被视为一种独立的恶性疾病，并且已经开发了仅专注于EGJC的治疗方法。最近的一项多中心前瞻性研究揭示了淋巴结转移的频率，并确定了淋巴结清扫的最佳范围。在围手术期治疗中,多药联合化疗，放射治疗,分子靶向治疗,而免疫治疗有望改善预后。在这次审查中,我们总结了以往的临床试验及其关于EGJC手术和围手术期治疗的重要证据.
